Alzheimer's Disease Patents (Class 514/17.8)
-
Publication number: 20140030274Abstract: A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The chaperone protein is or has a high identity to the Brichos domains of Bri2, Bri3 or proSP-C from human. Monomers of the chaperone proteins and/or compounds that promote formation of these monomers are useful for medical treatment of the condition.Type: ApplicationFiled: March 30, 2012Publication date: January 30, 2014Applicant: AlphaBeta ABInventors: Jan Johansson, Jenny Presto
-
COMPOSITION AND METHOD FOR REDUCING TISSUE DAMAGE FROM INFLAMMATORY DISORDER OR PATHOGENIC INFECTION
Publication number: 20140030251Abstract: Compositions and methods for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infections are described. In one aspect, a method for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infection comprises administering to a subject a therapeutically effective amount of a neuregulin. In another aspect, the composition comprises one or more active agents that: (a) increase expression or activity of a neuregulin; (b) inhibit the expression or activity of CXCL10, STAT3 or HEME; or (c) both (a) and (b).Type: ApplicationFiled: July 24, 2012Publication date: January 30, 2014Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: Byron D. Ford, Jonathan Stiles, Gregory Ford -
Patent number: 8637465Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.Type: GrantFiled: May 27, 2009Date of Patent: January 28, 2014Assignee: Kobenhavns UniversitetInventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
-
Patent number: 8632776Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: GrantFiled: February 25, 2011Date of Patent: January 21, 2014Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20140018300Abstract: The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions.Type: ApplicationFiled: July 8, 2013Publication date: January 16, 2014Inventor: VICTOR E. SHASHOUA
-
Publication number: 20140011744Abstract: This invention relates to a method of inhibiting neuronal cell death, including protecting neuronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP to prevent and/or treat a number of brain conditions, such as hypoxia-ischemia and brain alkalosis or various brain or spinal cord injuries due to physical or physiological stresses. In one aspect the invention provides a use of TCAP to increase ?-tubulin, ?-actin levels in neuronal cells and/or to increase fasciculation among neuronal cells, in culture or in tissue. In another aspect, the invention provides a method of treating various pH induced neuronal conditions.Type: ApplicationFiled: June 19, 2012Publication date: January 9, 2014Inventors: David LOVEJOY, Arij Al Chawaf
-
Patent number: 8623374Abstract: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid ? peptide that induces an enhanced immune response. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid ? peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid ? peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.Type: GrantFiled: August 29, 2011Date of Patent: January 7, 2014Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Junichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki
-
Publication number: 20140004172Abstract: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.Type: ApplicationFiled: June 28, 2012Publication date: January 2, 2014Inventors: Massimo MASSERINI, Francesca RE, Giulio SANCINI, Gianluigi FORLONI, Mario SALMONA
-
Patent number: 8617566Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: May 13, 2013Date of Patent: December 31, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
-
Publication number: 20130345142Abstract: This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.Type: ApplicationFiled: July 1, 2013Publication date: December 26, 2013Applicants: Mayo Foundation for Medical Education and Research, Vib VZW, The University of Manchester, The University of British Columbia, Universiteit AntwerpenInventors: Michael L. Hutton, Matthew Charles Baker, Jennifer Mae Gass, Rosa Rademakers, Jason Eriksen, Stuart M. Pickering-Brown, Ian Reid Alexander Mackenzie, Howard Feldman, Samir Kumar-Singh, Christine Van Broeckhoven, Marc Cruts, Ashley Diane Cannon
-
Patent number: 8613923Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: GrantFiled: June 12, 2008Date of Patent: December 24, 2013Assignees: AC Immune S.A., Genentech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Patent number: 8613929Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: July 21, 2011Date of Patent: December 24, 2013Assignee: TO-BBB Holding B.V.Inventors: Pieter J. Gaillard, Albertus G. De Boer, Arjen Brink
-
Patent number: 8614191Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (A?), a cause of dementia, and is thus useful in preventing or treating a neurological disease including Alzheimer's disease.Type: GrantFiled: February 2, 2012Date of Patent: December 24, 2013Assignee: Medipost Co., Ltd.Inventors: Yoon-Sun Yang, Won Il Oh, Jong Wook Chang, Ji Hyun Kim
-
Publication number: 20130338076Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.Type: ApplicationFiled: August 26, 2013Publication date: December 19, 2013Applicant: Tel Aviv University Future Technology Development L.P.Inventor: Ehud GAZIT
-
Publication number: 20130338075Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Inventor: Thien Nguyen
-
Patent number: 8609810Abstract: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS).Type: GrantFiled: May 26, 2010Date of Patent: December 17, 2013Assignee: Ruprecht-Karls-Universitat HeidelbergInventors: Peter Nawroth, Angelika Bierhaus, Thomas Fleming
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Publication number: 20130331330Abstract: Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the Helicobacter pylori protein CagA block phosphorylation of tau in neuronal cells and thereby decrease the deposition of neurofibrillary tangles and the toxic effects of Abeta-42.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Bingwei Lu, Jayakumar Rajadas, Dhananjay Wagh, Wendou Yu
-
Patent number: 8603487Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD), including diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI).Type: GrantFiled: April 14, 2009Date of Patent: December 10, 2013Assignee: AC Immune S.A.Inventors: Andrea Pfeifer, Claude Nicolau
-
Publication number: 20130324458Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: David GLASS, Shou-Ih HU
-
Patent number: 8597660Abstract: Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided.Type: GrantFiled: September 29, 2011Date of Patent: December 3, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Harish C. Pant, Ya-li Zheng, Niranjana D. Amin, Philip Grant, Parvathi Rudrabhatla, Varsha Shukla, Sashi Kesavapany
-
Publication number: 20130316955Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.Type: ApplicationFiled: January 9, 2012Publication date: November 28, 2013Applicant: MERCK PATENT GMBHInventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Brigitta Leuthner
-
Publication number: 20130316942Abstract: The present invention relates to potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having these properties, and to methods and uses of such short peptides in clinical and cosmetic applications.Type: ApplicationFiled: August 9, 2013Publication date: November 28, 2013Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8592379Abstract: The present invention provides a metastin derivative represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition containing it. The metastin derivative or a salt thereof is superior in blood stability, and has a cancer metastasis suppressive action or cancer growth suppressive action.Type: GrantFiled: April 28, 2009Date of Patent: November 26, 2013Assignees: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita
-
Patent number: 8586548Abstract: The invention relates to compositions and methods to confer protection on neurons. Peptides derived from the NAPVSIPQ (SEQ ID NO:4) peptide and including branched amino acids, such as alpha-aminoisobutyric acid, are included. Also included are methods of preventing and treating neurodegenerative disorders and damage caused by neurotoxic substances.Type: GrantFiled: August 16, 2010Date of Patent: November 19, 2013Assignee: Ramot at Tel-Aviv University, Ltd.Inventor: Illana Gozes
-
Publication number: 20130302292Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.Type: ApplicationFiled: April 26, 2013Publication date: November 14, 2013Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
-
Publication number: 20130302343Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like-molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R-?1, IL-12R-?2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.Type: ApplicationFiled: January 4, 2012Publication date: November 14, 2013Applicants: CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN, UNIVERSITAT ZURICHInventors: Burkhard Becher, Frank Heppner
-
Patent number: 8569240Abstract: The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient.Type: GrantFiled: August 14, 2011Date of Patent: October 29, 2013Assignee: Regeron, Inc.Inventors: Heejae Lee, Jong-Seon Byun, Kyung Young Lee, Dahlkyun Oh
-
Patent number: 8569242Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.Type: GrantFiled: December 27, 2011Date of Patent: October 29, 2013Assignee: The Regents of the University of CaliforniaInventor: Katerina Akassoglou
-
Publication number: 20130273035Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: ApplicationFiled: March 19, 2013Publication date: October 17, 2013Inventor: The J. David Gladstone Institutes
-
Patent number: 8557864Abstract: A method for preventing or treating a nervous disorder can include administrating to a person in need of such prevention or treatment a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid. The ester of the decenoic acid can be selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-3-decenoic acid ethyl ester, trans-9-decenoic acid methyl ester, and trans-9-decenoic acid ethyl ester.Type: GrantFiled: April 4, 2012Date of Patent: October 15, 2013Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Munekazu Iinuma, Shoei Furukawa
-
Publication number: 20130266663Abstract: Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal.Type: ApplicationFiled: April 29, 2011Publication date: October 10, 2013Inventors: Arthur Brown, Sandy Gian Vascotto
-
Publication number: 20130261053Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicants: ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130263298Abstract: A transgenic fly whose genome is modified to express enhanced levels of glutamate-cysteine ligase (GCL) gene is provided. The fly displays phenotypes associated with Alzheimer's disease (AD). Further, a method for diagnosing AD is provided, which includes assessing enzymatic activities in mitochondrial enzymes. Glutathione pathway are investigated by creating Alzheimer's model Drosophila with over-expression of the GCLc gene, inducing redox stress through sleep deprivation, and analyzing mitochondrial electron transport chain (ETC) using colorimetric enzymatic assays. For prevention of AD, it is proposed that the epigenetic approaches be used to increase glutathione levels in vivo before the onset of AD. For treatment of AD, it is proposed that the glutathione levels be increased by GCLc modulation.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicant: INDIGO CAPITAL GROUP LLCInventors: Lisa P. MICHAELS, Tess P. Michaels
-
Publication number: 20130251639Abstract: The invention relates to novel cyclodecapeptide compounds having formula (I) for use as drugs and, more specifically, for use in the diagnosis, prevention and/or treatment of neurodegenerative diseases, such as Wilson's disease and Alzheimer's disease, and for use in the diagnosis, prevention and/or treatment of poisoning with metal ions, such as copper and mercury ions. The invention also relates to pharmaceutical compositions comprising at least one compound having formula (I) as an active principle.Type: ApplicationFiled: May 17, 2011Publication date: September 26, 2013Applicant: UNIVERSITE JOSEPH FOURIERInventors: Pascale Delangle, Anaïs Pujol, Pascal Dumy, Olivier Renaudet, Michel Ferrand
-
Publication number: 20130252901Abstract: A peptide compound of the following general formula (I) or (II): Ra—R1—R2—R3—R4—Rb??(I) or Ra—R4—R3—R2—R1—Rb??(II) wherein, R1 is a residue of amino acid H, R or K; R2 is a residue of amino acid A; R3 is a residue of amino acid E or D; R4 is a residue of amino acid E or D, Ra represents the N-terminal primary amine functions of the amino acid R1 or R4, either free or substituted with a protective group, Rb represents the hydroxyl function of the C-terminal carboxyl group of the amino acid R1 or R4, either free or substituted with a protective group.Type: ApplicationFiled: October 24, 2011Publication date: September 26, 2013Inventors: Oleg Mediannikov, Alexander Morozov
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Publication number: 20130244946Abstract: Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof.Type: ApplicationFiled: May 22, 2013Publication date: September 19, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Ronit SHALTIEL-KARYO, Ehud Gazit
-
Publication number: 20130236447Abstract: Inhibition of eIF-2? phosphorylation can be used to improve cognitive function and/or to treat dementia, including Alzheimer's Disease. In particular, this can be achieved by inhibiting the kinase activity of PKR in a non-toxic manner.Type: ApplicationFiled: December 17, 2012Publication date: September 12, 2013Applicant: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP., LTD.Inventors: Yaacov ROSENBLUM, Elad STERN, Yifat SEGEV
-
Publication number: 20130236509Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.Type: ApplicationFiled: July 14, 2011Publication date: September 12, 2013Applicant: DELTA CRYSTALLON B.V.Inventor: Johannes Maria Van Noort
-
Publication number: 20130231290Abstract: The present invention relates to methods of diagnosing, treating and prognosing mental disorders, such as Alzheimer's Disease. In one embodiment, the present invention provides a method of treating Alzheimer's Disease by inhibiting dysfunctional signaling of ?7 nAChRs in the medial septum region of an individual.Type: ApplicationFiled: November 18, 2011Publication date: September 5, 2013Applicant: DIGNITY HEALTHInventor: Jie Wu
-
Publication number: 20130224163Abstract: The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1.Type: ApplicationFiled: November 7, 2011Publication date: August 29, 2013Inventors: Brian P. Head, Piyush M. Patel, Hemal Patel, David m. Roth
-
Publication number: 20130225478Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.Type: ApplicationFiled: July 19, 2011Publication date: August 29, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Avner Fink, Eliran-Moshe Reuven, Liraz Shmuel-Galia
-
Publication number: 20130225498Abstract: There is provided a composition for preventing or treating neurodegenerative diseases, including one or two or more selected from the group consisting of a chemoattractant CCL5, a CCL5 expression regulator, and a CCL5 activator as an active ingredient, in which by confirming through a morris water maze task that the CCL5 recovers memory loss and improves spatial cognition ability, it has been found that the composition including any one or two or more selected from the group consisting of the CCL5, the CCL5 expression regulator, and the CCL5 activator can be usefully employed as a pharmaceutical composition or a food composition for preventing or treating neurodegenerative diseases.Type: ApplicationFiled: October 22, 2012Publication date: August 29, 2013Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventor: Kyungpook National University Industry-Academic
-
Patent number: 8518885Abstract: A novel class of peptide ?-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA2-AA1-CO—NH—(CH2)n—R3. Processes for the synthesis of peptidyl ?-ketoamide derivatives. Compositions and methods for inhibiting cysteine proteases, inhibiting calpains, and treating disease caused by cysteine proteases and calpains are provided.Type: GrantFiled: July 16, 2008Date of Patent: August 27, 2013Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: James C. Powers, Jonathan D. Glass, Asli Ovat, Zhaozhao Li
-
Patent number: 8512709Abstract: An object of the invention is to provide a peptide based on a sequence of an amyloid ? peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine or a cysteine analogue, and a method for enhancing immune response to amyloid ? using said peptide, a medicament for prophylaxis and treatment of Alzheimer disease using said amyloid ? peptide that induces an enhanced immune response, and a DNA vaccine comprising a gene coding for an amyloid ? peptide or a sequence derived from an amyloid ? peptide with addition or insertion of cysteine or a cysteine analogue, as expected to be similarly efficacious.Type: GrantFiled: October 16, 2009Date of Patent: August 20, 2013Assignee: The Chemo-Sero-Therapeutic Research InstitueInventors: Junichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki
-
Publication number: 20130209549Abstract: The subject invention concerns materials and methods for treating neurodegenerative diseases and conditions associated with aggregation of the microtubule-associated protein tau. A method of the invention comprises administering an effective amount of a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a person or animal in need of treatment. In one embodiment, a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, is contacted with or provided to a target cell. The target cell can be a neuron. In a specific embodiment, an Hsp27 is delivered to the target cell via a polynucleotide encoding an Hsp27 protein, or a biologically-active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g.Type: ApplicationFiled: July 21, 2011Publication date: August 15, 2013Applicant: UNIVERSITY OF SOUTH FLORIDAInventor: Chad Dickey
-
Publication number: 20130210704Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: S&T GLOBAL INC.Inventor: S&T Global Inc.
-
Publication number: 20130209439Abstract: The present invention provides methods and materials for use in increasing HSP20 activation in a biological system, for example by increasing phosphorylation of Ser16 of HSP20. In one aspect, the invention provides a method for increasing HSP20 activation in a biological system, comprising contacting the system with an antagonist capable of inhibiting PDE4 binding to HSP20, the antagonist comprising or consisting essentially of a fragment of PDE4 or an analogue thereof. In a further aspect the invention provides a method of screening for an agent able to increase activation of HSP20. A preferred antagonist has a C-terminal lysine residue.Type: ApplicationFiled: October 7, 2011Publication date: August 15, 2013Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOWInventors: George S. Baillie, Miles Houslay, Jon Day
-
Publication number: 20130210738Abstract: The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition.Type: ApplicationFiled: December 24, 2010Publication date: August 15, 2013Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITYInventors: Myeong Ok Kim, M.L Narsimhan, M.L Naseer, R.A Bressan, Dae Jin Yun, Hae Young Lee